Search PubMed⌕ Search

Biomedical subjects

B Patsner

Publications and source records attributed to B Patsner.

At least 55 records · Page 3Linked to original sources
PubMed1990

Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma.

Serum CA 125 levels were normal preoperatively in 123 of 125 (98.4%) patients with clinical and surgical stage I or II endometrial adenocarcinoma, and remained so in all patients who remained without evidence of either isolated vaginal recurrence or postoperative radiation enteritis. Recurrent disease developed in 13 patients. All of those who had pelvic (1), abdominal (4), or pulmonary (2) metastases had elevated serum CA 125 levels. None of the six patients with isolated vaginal recurrences had elevated CA 125 levels. Four patients had small bowel obstruction as a result of postoperative pelvic radiation, and all had elevated CA 125 levels during these episodes, although no evidence of recurrent disease was found during exploratory laparotomy for intestinal bypass. Serum CA 125 levels may have a role in the posttreatment surveillance of patients with early-stage endometrial carcinoma, but may be falsely elevated in the presence of severe radiation injury and at a normal level in the presence of isolated vaginal metastases.

Adenocarcinoma↗
PubMed1990

Continuous or interrupted fascial closure: a prospective evaluation of No. 1 Maxon suture in 402 gynecologic procedures.

During a 14-month period of using a long-term absorbable suture (No. 1 Maxon), 402 patients were entered into a prospective, randomized trial of fascial closure. Patients were randomized between a continuous closure (201 patients) and an interrupted en bloc (201 patients) technique. Each patient was subjected to a preoperative and intraoperative protocol for wound management. There were no acute wound failures. Wound infection rates and risk of hernia were not apparently affected by closure technique.

Adult↗
PubMed1990

Single-dose antibiotic prophylaxis for patients undergoing extended pelvic surgery for gynecologic malignancy.

The comparative efficacy of single-dose antibiotic prophylaxis was retrospectively evaluated in 116 patients undergoing extended pelvic surgical procedures with curative intent. During the 24-month period, other important variables such as surgeon's experience, duration of preoperative hospitalization, preoperative preparation, method of hair removal, suture type, suture size, use of drains, use of cautery, and abdominal closure were controlled. The overall surgical site infection rate was 4.3% after radical hysterectomy with lymphadenectomy and 4.5% after total hysterectomy with lymphadenectomy. In this clinical situation the use of a single dose of antibiotic prophylaxis theoretically decreases cost and patient exposure and appears to be as efficacious as a multiple-dose regimen.

Anti-Bacterial Agents↗
PubMed1990

Intestinal complications associated with use of the Dexon mesh sling in gynecologic oncology patients.

Three cases of postoperative enterocutaneous fistula formation following use of the Dexon mesh sling are reported from two gynecologic oncology services. Two patients had intestinal trauma or bowel resection at the time of mesh placement. Postoperative submesh abscess formation was noted in only one patient. Factors which might predispose to fistula formation after mesh placement, particularly in previously radiated patients, and techniques which might be used to avoid this complication are discussed.

Adult↗
PubMed1990

Stapler resection of Meckel's diverticulum during gynecologic cancer surgery.

Stapler resection of Meckel's diverticulum was performed on 16 patients with known or presumed gynecologic malignancy at the time of extended abdominal surgery. All diverticulectomies were done quickly and without morbidity. Heterotropic gastric epithelium was found in one diverticulum, and one other patient with stage III ovarian adenocarcinoma had metastases to the serosa of her Meckel's diverticulum.

Adult↗
PubMed1990

Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?

The records of 125 patients with nonmucinous invasive ovarian adenocarcinoma who underwent cytoreductive surgery, cisplatin-based combination chemotherapy, and second-look laparotomy were analyzed to correlate pre-second-look serum CA-125 levels with the size of residual ovarian cancer. The majority of patients with negative second-look laparotomy had normal serum CA-125 levels (46/50 or 92%). Of the 75 patients with positive second-look, 56 (75%) had normal CA-125 levels preoperatively. Twenty-three of twenty-four (96%) patients with residual disease less than or equal to 1 cm had normal CA-125 levels as did 20 of 28 (71%) patients with disease 1.1-2.0 cm. Although elevated serum CA-125 levels were invariably associated with visible/gross disease and increasing size of residual disease tended to be associated with increasing elevations of CA-125, normal CA-125 levels often occurred in the presence of large-volume (greater than 2 cm) disease (13/23, 57% of patients). The considerable overlap of serum CA-125 levels for all sizes of residual disease precluded precise prediction of residual disease size based on serum CA-125 level alone.

Adenocarcinoma↗
PubMed1990

Morbidity and mortality of stapled anastomoses on a gynecologic oncology service: a retrospective review.

The Gynecologic Oncology Division performed 167 operations requiring intestinal resection during the period July 1, 1980 to May 30, 1989. Stapling instruments were utilized in 155 procedures and resulted in 204 anastomoses. Major morbidity occurred in 36 (23%) patients, including 17 (11%) deaths and (4.5%) fistulas. Minor morbidity, such as ileus and atelectasis, occurred in 46 (30%) patients. Intestinal surgery is required in approximately 10% of gynecologic oncology procedures, and is associated with significant major and minor morbidity, particularly in obstructed patients.

Adolescent↗
PubMed1990

Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?

The records of 125 patients with nonmucinous invasive ovarian adenocarcinoma who underwent cytoreductive surgery, cisplatin-based combination chemotherapy, and second-look laparotomy were analyzed to correlate pre-second-look serum CA-125 levels with the size of residual ovarian cancer. The majority of patients with negative second-look laparotomy had normal serum CA-125 levels (46/50 or 92%). Of the 75 patients with positive second-look, 56 (75%) had normal CA-125 levels preoperatively. Twenty-three of twenty-four (96%) patients with residual disease less than or equal to 1 cm had normal CA-125 levels as did 20 of 28 (71%) patients with disease 1.1-2.0 cm. Although elevated serum CA-125 levels were invariably associated with visible/gross disease and increasing size of residual disease tended to be associated with increasing elevations of CA-125, normal CA-125 levels often occurred in the presence of large-volume (greater than 2 cm) disease (13/23, 57%). The considerable overlap of serum CA-125 levels for all sizes of residual disease precluded precise prediction of residual disease size based on serum CA-125 level alone.

Adenocarcinoma↗
PubMed1990

Management of low-grade cervical dysplasia during pregnancy.

Fifty-five pregnant patients referred to my colposcopy service from 1985 to 1990 for biopsy-proven mild dysplasia were entered into a program of serial evaluations, including Pap test, colposcopy, and directed biopsy if indicated. The evaluations were done every 12 weeks during pregnancy and at 6 weeks postpartum to rule out new or occult invasive cervical cancer. By the time the postpartum biopsy was done, no such cancer had been detected. All 55 patients had mild dysplasia or less. I conclude that pregnant patients with biopsy-proven mild cervical dysplasia who have had adequate expert colposcopy and results of Pap test consistent with biopsy require only one antepartum colposcopy prior to postpartum reevaluation and treatment. Multiple interval cytologic and colposcopic studies with or without biopsy are unnecessary. The likelihood of invasive cervical cancer developing in these patients during pregnancy is negligible.

Adolescent↗
PubMed1990

Preoperative serum CA-125 levels in early stage ovarian cancer.

Preoperative serum CA 125 levels were elevated in only 23% (9/39) of patients with FIGO Stage I invasive ovarian epithelial carcinoma whereas 88% of patients with Stages II-IV disease had elevated CA 125 levels preoperatively. No preoperative serum CA 125 levels in any patient with Stage I disease exceeded 300 U/ml.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1990

Topical podofilox for the treatment of condylomata acuminata in women.

The purpose of this study was to determine the efficacy and safety of 0.5% podofilox solution (Condylox) for the treatment of genital warts in women. Thirty-seven women with anogenital warts applied the solution to the surface of these warts twice daily for 3 days, followed by 4 drug-free days. A minimum of two and a maximum of four treatment cycles were given. The subjects were evaluated weekly for the first 4 weeks and again at 6 and 10 weeks. At the end of 10 weeks, the mean number of warts per patient was reduced from 6.27 to 1.1, and half of the patients were completely cleared of warts. Only eight of 37 subjects (21.6%) developed new warts during the study period. Approximately 15% of patients reported "severe" local reactions to the treatment after the first treatment cycle, but this was reduced to only 5% by the last treatment cycle. During the same period, the patients reporting no side effects increased from 44 to 86%. The only woman who discontinued the study did so because of dizziness and epigastric discomfort, probably unrelated to drug use. Thus, 0.5% podofilox solution appears to be an effective treatment for condylomata acuminata, with acceptable side effects that are local and temporary.

Administration, Topical↗
PubMed1990

Carbon dioxide laser vaporization of diaphragmatic metastases for cytoreduction of ovarian epithelial cancer.

Three patients with International Federation of Gynecology and Obstetrics state IIIC ovarian adenocarcinoma underwent CO2 laser vaporization of large-volume (5-6 cm) and miliary right hemidiaphragmatic metastases at the conclusion of standard debulking surgery to effect optimal cytoreduction. Destruction of diaphragmatic metastases was accomplished rapidly with no added morbidity or blood loss. The hand-held CO2 laser is a useful modality for removal of isolated large- and small-volume diaphragmatic disease, particularly if only the peritoneum is involved, and avoids the morbidity that may accompany entry into the pleural space.

Adenocarcinoma↗